NASDAQ
11.77USD
+0.25 (+2.17%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
575.4M
P/E
—
EPS
—
Beta
2.18
52W range
2.22-14.53
Day range
11.53–11.91
Open
11.66
Prev close
11.52
Volume
266.3K
Avg volume
531.9K
Dividend
0.00
IPO
2024-07-19
https://www.globenewswire.com/news-release/2026/06/08/3307910/0/en/Artiva-Biotherapeutics-Highlights-AlloNK-Data-Presented-at-EULAR-2026-FDA-RMAT-Designation-in-Refractory-Rheumatoid-Arthritis-and-Webcast-Today.html · 6/8/2026+1.00
https://www.globenewswire.com/news-release/2026/05/19/3297953/0/en/Artiva-Biotherapeutics-Announces-Multiple-AlloNK-Data-Presentations-at-EULAR-2026-Congress-Including-Late-Breaking-Oral-Presentation-Highlighting-Clinical-Efficacy-Comparable-to-Au.html · 5/19/2026+0.80
https://seekingalpha.com/article/4901714-artiva-biotherapeutics-buy-allonk-poc-fda-phase-3-alignment-refractory-ra · 5/8/2026+1.00
https://www.globenewswire.com/news-release/2026/05/08/3290975/0/en/Artiva-Biotherapeutics-Announces-Pricing-of-300-Million-Underwritten-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html · 5/8/2026
https://www.defenseworld.net/2026/02/16/artiva-biotherapeutics-inc-nasdaqartv-short-interest-down-28-5-in-january.html · 2/16/2026+0.30
https://www.globenewswire.com/news-release/2025/10/30/3177964/0/en/Artiva-Biotherapeutics-to-Participate-in-Upcoming-Investor-Conferences-in-November.html · 10/30/2025+0.20
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
